EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

GLP-1 receptor agonist associated unmasking of insulinoma

Eden Simonov, Rina Berger, Olga Shishkina, Alexander Sivokha, Dror Cantrell

European Journal of Case Reports in Internal Medicine · 05.05.2026 · 13 (5)

DOI: 10.12890/2026_006552 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Case Reports in Internal Medicine, online erschienen am 05.05.2026. Verfasst von Eden Simonov und 4 weiteren Autor:innen. Beteiligte Einrichtung: Maccabi Healthcare Services (MHS), Bat Yam, Israel. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Insulinoma is a rare functional pancreatic neuroendocrine tumour and the most common cause of endogenous hyperinsulinaemic hypoglycaemia in adults. Diagnosis is frequently delayed due to non-specific and intermittent symptoms, and a high index of suspicion is needed. Case description: We report the case of a 40-year-old non-diabetic woman who presented with recurrent episodes of weakness shortly after initiation of a glucagon-like peptide-1 receptor agonist (GLP-1RA). Laboratory evaluation demonstrated inappropriately elevated insulin and C-peptide levels during documented hypoglycaemic events, consistent with endogenous hyperinsulinaemia. Autoimmune and exogenous causes were excluded. Imaging studies identified a 2 cm hypervascular pancreatic lesion, with functional imaging confirming somatostatin receptor avidity consistent with an insulin-secreting tumour. The patient was initially treated with diazoxide as a bridge to definitive management. She subsequently underwent laparoscopic distal pancreatectomy, with histopathology confirming a well-differentiated pancreatic neuroendocrine tumour (WHO Grade 1). Following surgery, hypoglycaemia resolved completely.

Conclusion

This case highlights the potential of GLP-1 receptor agonist therapy to unmask an insulinoma. Many benign insulinomas exhibit abundant expression of GLP-1 receptors. While a high index of suspicion remains essential, awareness of the emerging association between the incretin-based therapies and unexplained hypoglycaemia may facilitate earlier diagnosis.

Schlagwörter

Stichwörter der Autor:innen

Insulinomaglucagon-like peptide-1 receptor agonists (GLP-1RAs)hypoglycaemia

Autor:innen und Institutionen

  • Maccabi Healthcare Services (MHS), Bat Yam, Israel.
  • Internal Medicine 'C', Shamir Medical Center, Zerifin, Israel, affiliated to the Gray Faculty of Medical & Health Sciences, Tel Aviv University, Tel Aviv, Israel.
  • Department of Radiology, Shamir Medical Center, Zerifin, Israel, affiliated to the Gray Faculty of Medical & Health Sciences, Tel Aviv University, Tel Aviv, Israel.
  • Endocrine Institute, Shamir Medical Center, Zerifin, Israel, affiliated to the Gray Faculty of Medical & Health Sciences, Tel Aviv University, Tel Aviv, Israel.

Zitieren

APA

Simonov, E., Berger, R., Shishkina, O., Sivokha, A., & Cantrell, D. (2026). GLP-1 receptor agonist associated unmasking of insulinoma. European Journal of Case Reports in Internal Medicine, 13(5). https://doi.org/10.12890/2026_006552

Vancouver

Simonov E, Berger R, Shishkina O, Sivokha A, Cantrell D. GLP-1 receptor agonist associated unmasking of insulinoma. European Journal of Case Reports in Internal Medicine. 2026;13(5). doi:10.12890/2026_006552

BibTeX
@article{Simonov2026,
  author = {Simonov, Eden and Berger, Rina and Shishkina, Olga and Sivokha, Alexander and Cantrell, Dror},
  title = {GLP-1 receptor agonist associated unmasking of insulinoma},
  journal = {European Journal of Case Reports in Internal Medicine},
  year = {2026},
  volume = {13},
  number = {5},
  doi = {10.12890/2026_006552}
}
Kostenlos starten →